Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Your Daily Pharma Scoop: Dynavax Achieves Major Milestone, GW Pharmaceuticals GWP42006 Fails, Sangamo Signs Deal With Gilead's Kite Unit

2018-02-23 seekingalpha
Today we will discuss Dynavax Technologies (DVAX), which made further progress in its commercialization efforts for Hepatitis B vaccine HEPLISAV-B. (119-0)

Ligand (LGND) Q4 Earnings & Revenues Top, 2018 View Solid

2018-02-22 zacks
Ligand Pharmaceuticals Incorporated (LGND - Free Report) reported fourth-quarter 2017 adjusted earnings of $1.31 per share, significantly up 77% from the year-ago figure of 74 cents. The bottom line also beat the Zacks Consensus Estimate of $1.06. (90-0)

Ligand Pharmaceuticals' (LGND) CEO John Higgins on Q4 2017 Results - Earnings Call Transcript

2018-02-22 seekingalpha
Good day. My name is Shikander [ph] and I will be your conference operator for today's call. At this time, I'd like to welcome everyone to Ligand's Fourth Quarter 2017 Earnings Release Conference Call. [Operator Instructions]. I now turn things over to Todd Pettingill, Director of Corporate Development and Investor Relations. (41-1)

What's in Store for Ligand (LGND) This Earnings Season?

2018-02-19 zacks
Ligand Pharmaceuticals Incorporated (LGND - Free Report) is scheduled to report fourth-quarter 2017 results on Feb 21, after the market closes. Ligand’s earnings history has been a mixed bag with the company surpassing expectations in two of the last four quarters and missing in the other two. It also delivered an average beat of 8.22%. (76-0)

Ligand Pharma Is A Short

2018-01-30 seekingalpha
Ligand does not have a Captisol manufacturing capability and is dependent upon a sole source of supply. (3-0)

Viking Therapeutics: VK5211 Prospects Going Forward

2018-01-25 seekingalpha
Non-steroidal selective androgen receptor modulators (SARMs) are long known to increase lean body mass but have questions of safety and clinical usefulness. (22-1)

10 Risky (But Rewarding) Small-Cap Stocks to Buy Now | InvestorPlace

2018-01-23 investorplace
With the market up 22% up over the course of the past year, led by giants like Amazon.com, Inc. (NASDAQ:AMZN) and Facebook, Inc. (NASDAQ:FB), investors might fear that a pullback is just around the corner. And maybe one is. (295-9)

10 Stocks to Buy Instead of Bitcoin

2018-01-19 investorplace
There certainly has been a lot of talk about cryptocurrencies, especially bitcoin, in the past few weeks. It’s not surprising. Every investor loves the zero-to-hero story, although most never realize that dream. (65-3)

LGND / Ligand Pharmaceuticals Incorporated - Stock Institutional Ownership and Shareholders - Fintel.io

2018-01-19 fintel.io
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has 287 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 24,676,912 shares. Largest shareholders include BlackRock Inc., Vanguard Group Inc, William Blair Investment Management, Llc, Bank Of America Corp /de/, State Street Corp, Knott David M, Henderson Group Plc, Victory Capital Management Inc, Cardinal Capital Management Llc /ct, and FMR LLC / Fidelity. (166-0)

5 Big Biotech Stocks To Buy In 2018

2018-01-17 investorplace
While most investors tend to think of biotech stocks as pure lotto tickets, the reality is the sector is much more nuanced than that. Sure, there are bootstrapped, clinical-stage biotech stocks with only one potential drug in their arsenal. These are the ones that live or die by the FDA and clinical trials. (133-1)

Ligand (LGND) Inks Deal With Glenmark for OmniAb Platform

2018-01-12 zacks
Ligand Pharmaceuticals Incorporated (LGND - Free Report)  announced that it has inked a worldwide license agreement with global innovative pharmaceutical company, Glenmark Pharmaceuticals. Per the agreement, Glenmark will be able to use the full OmniAb platform for producing mono- and bispecific human therapeutic antibodies. (15-0)

Biotech Stock Roundup: GWPH Submits Epidiolex in the EU, Sangamo Inks Deal with Pfizer

2018-01-04 zacks
Although it was a slow week, a few companies announced collaboration agreements. Meanwhile, Ligand Pharmaceuticals (LGND - Free Report) raised its guidance for 2017 and GW Pharmaceuticals (GWPH - Free Report) got priority review in the United States for Epidiolex. Recap of the Week’s Most Important Stories GW’s Epidiolex Submitted for EU Approval: GW Pharmaceuticals, which has been in the news for its lead cannabinoid pipeline candidate, Epidiolex (cannabidiol or CBD), said that it has submitted a regulatory application to the European Medicines Agency (“EMA”) for Epidiolex as adjunctive treatment for seizures associated with Lennox-Gastaut syndrome (“LGS”) and Dravet syndrome. (425-0)

BRIEF-Ligand Pharmaceuticals - Expects Reduction Of Corporate Tax Rate To Reduce Deferred Tax Asset On Balance Sheet By About $40 Mln

2017-12-26 reuters
* LIGAND PHARMACEUTICALS - EXPECTS REDUCTION OF CORPORATE TAX RATE TO REDUCE DEFERRED TAX ASSET ON BALANCE SHEET BY ABOUT $40 MILLION AS OF SEPT 30, 2017 Source text: (bit.ly/2zy8ap7) Further company coverage: (3-0)

Biotech Stock Risks & Returns: An Understanding Today

2017-12-20 seekingalpha
Comparing the likely coming price ranges of a couple dozen industry-leader stocks as forecast by Market-Makers, LGND and AMGN have capital gains appeal. (82-2)


CUSIP: 53220K199